New hope for kids with tough cancers: testing a powerful drug duo
NCT ID NCT06521567
Summary
This study is testing a new combination of two drugs, cobolimab and dostarlimab, for children and young adults with advanced solid tumors that have not responded to other treatments. The main goals are to find the safest and most effective dose and to see how well the body tolerates the treatment. Researchers will also check if the treatment helps shrink tumors in certain cancers like melanoma and Hodgkin lymphoma.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Los Angeles, California, 90048, United States
-
GSK Investigational Site
Iowa City, Iowa, 52242, United States
-
GSK Investigational Site
Hackensack, New Jersey, 07601, United States
-
GSK Investigational Site
Cincinnati, Ohio, 45229, United States
-
GSK Investigational Site
Providence, Rhode Island, 02903, United States
-
GSK Investigational Site
Madison, Wisconsin, 53792, United States
-
GSK Investigational Site
Brno, 61300, Czechia
-
GSK Investigational Site
Phaha 5, 15006, Czechia
-
GSK Investigational Site
Copenhagen, 2100, Denmark
-
GSK Investigational Site
Bordeaux, 33076, France
-
GSK Investigational Site
Lyon, 69373, France
-
GSK Investigational Site
Paris, 75248, France
-
GSK Investigational Site
Strasbourg, 67098, France
-
GSK Investigational Site
Villejuif, 94805, France
-
GSK Investigational Site
Bologna, 40138, Italy
-
GSK Investigational Site
Naples, 80123, Italy
-
GSK Investigational Site
Barcelona, 08035, Spain
-
GSK Investigational Site
Madrid, 28009, Spain
-
GSK Investigational Site
Madrid, 28046, Spain
-
GSK Investigational Site
Valencia, 46026, Spain
Conditions
Explore the condition pages connected to this study.